Motor neurone disease (MND) is a group of progressive neurological conditions in which the nerve cells that control voluntary muscle movement gradually break down and die. As these motor neurons deteriorate, the muscles they supply weaken, waste away, and eventually stop working. The most common form is amyotrophic lateral sclerosis (ALS), but several other subtypes exist, each affecting different sets of nerve cells and progressing at different rates.
How Motor Neurons Work and What Goes Wrong
Your body has two main types of motor neurons. Upper motor neurons run from the brain down into the spinal cord, carrying signals that initiate and control movement. Lower motor neurons extend from the spinal cord out to the muscles themselves, delivering the final instruction to contract. In MND, one or both of these neuron types degenerate. When lower motor neurons are damaged, muscles weaken, shrink, and twitch. When upper motor neurons are damaged, muscles become stiff and movements become slow and clumsy.
The combination of upper and lower motor neuron damage is the hallmark of ALS. Other forms of MND sit at different points along this spectrum, with some affecting only upper neurons and others affecting only lower neurons. Regardless of the type, the disease is progressive, meaning symptoms spread to new areas of the body over time.
Types of Motor Neurone Disease
ALS is by far the most common form. It can affect both upper and lower motor neurons, causing rapid loss of muscle control and eventual paralysis. Most people diagnosed with MND have ALS.
Progressive bulbar palsy (PBP) targets the motor neurons in the brainstem, the region that controls swallowing, speaking, and chewing. Early symptoms include slurred speech, difficulty swallowing, and weakness in the tongue and facial muscles. Most experts consider PBP a variant of ALS because the majority of people who start with bulbar symptoms eventually develop more widespread muscle involvement.
Primary lateral sclerosis (PLS) affects only the upper motor neurons. It causes muscle stiffness, spasticity, slowed movement, and problems with balance and speech. PLS progresses slowly, often over years or even decades, making it the least aggressive form.
Progressive muscular atrophy (PMA) is an uncommon subtype that damages only the lower motor neurons. People with PMA typically notice weakness in their hands or feet first, which then spreads. Muscle wasting, cramping, and twitching are prominent features, and cold temperatures can worsen symptoms.
Early Symptoms to Recognize
MND often begins subtly. The first signs depend on which neurons and which body region are affected first. Limb-onset disease, the most common pattern, typically starts with weakness or clumsiness in one hand, arm, or leg. You might notice difficulty gripping objects, tripping more often, or a foot that drags when you walk. Muscle twitching (fasciculations) and cramps are common early features, though these are also extremely common in healthy people.
Bulbar-onset disease starts with changes in speech or swallowing. Words may sound slurred or nasal, and swallowing liquids or food may feel effortful. Some people notice their voice tiring more quickly than usual.
Because early symptoms overlap with many less serious conditions, diagnosis can take time. One important distinguishing feature of MND is that it does not affect sensation. If you have numbness, tingling, or pain as a primary symptom, another condition is more likely.
What Causes MND
For the vast majority of people, about 9 in 10, MND appears without any family history. These cases are called sporadic, and their exact cause remains unclear. A combination of genetic susceptibility, environmental exposures, and aging likely plays a role.
The remaining cases, roughly 1 in 10, are inherited. Researchers have identified the genes responsible for about 70% of familial cases. The most common is C9ORF72, which accounts for about 4 in 10 inherited cases. SOD1 is responsible for about 2 in 10, and TARDBP (sometimes referred to by the protein it produces, TDP-43) accounts for up to 5 in 100. Knowing which gene is involved matters increasingly for treatment, since some newer therapies target specific genetic mutations.
How MND Is Diagnosed
There is no single blood test or scan that confirms MND. Diagnosis relies on a combination of clinical examination, nerve and muscle testing, and ruling out other conditions that can mimic it. Doctors look for signs of both upper and lower motor neuron damage spreading across different body regions over time.
The current diagnostic standard, known as the Gold Coast criteria, requires either upper and lower motor neuron signs in at least one body region, or lower motor neuron signs in two or more regions, along with evidence that the disease is progressing and no better explanation for the symptoms. Electromyography (EMG), a test that measures electrical activity in muscles, plays a central role. It can detect patterns of nerve damage and muscle twitching that are characteristic of MND, even before symptoms become obvious in a particular area. Other tests like MRI scans and blood work are used primarily to exclude conditions such as spinal cord compression, nerve inflammation, or muscle diseases.
The diagnostic process can take several months. This delay is frustrating but reflects the care needed to distinguish MND from treatable conditions.
Prognosis and Disease Progression
MND varies considerably from person to person. Median survival after diagnosis ranges from about 20 to 48 months, but this number masks wide individual variation. Between 10% and 20% of people with MND survive beyond 10 years. The type of MND matters: PLS progresses over years or decades, while ALS with bulbar onset tends to progress more quickly.
As the disease advances, weakness spreads from the area where it started to other parts of the body. Most people eventually experience difficulty with breathing as the muscles that control the diaphragm weaken. Breathing complications are the most common cause of death in MND. Cognitive changes, ranging from mild shifts in behavior or thinking to a form of dementia affecting the frontal and temporal lobes, occur in a proportion of people with ALS.
Treatment and Symptom Management
No treatment reverses or stops MND, but several approaches can slow progression and improve quality of life. Riluzole is the longest-established medication and modestly extends survival. Newer treatments are beginning to target specific genetic forms of the disease. In 2023, the FDA approved tofersen for people with ALS caused by mutations in the SOD1 gene. It works by reducing levels of the harmful SOD1 protein and was approved based on its ability to lower a blood marker of nerve damage, though long-term clinical outcomes are still being studied. This approval was a milestone because it represented the first genetically targeted therapy for any form of MND.
For most people, day-to-day management centers on a team of specialists working together. Physiotherapists help maintain mobility and prevent joint stiffness. Speech and language therapists assist with communication strategies as speech becomes harder, including the use of assistive technology. Dietitians monitor nutrition, which is critical because weight loss is linked to faster disease progression. When swallowing becomes unsafe or insufficient, a feeding tube (gastrostomy) can help maintain nutrition and hydration.
Breathing support through non-invasive ventilation, a mask-based system that assists the diaphragm, can improve both survival and quality of life when introduced early. Some studies suggest it also reduces the energy the body spends on breathing, leaving more reserves for daily activities. However, up to 30% of people cannot tolerate it due to anxiety, excess saliva, claustrophobia, or discomfort. People with bulbar-onset disease are six times less likely to tolerate ventilation than those whose disease started in the limbs.
How Common Is MND
MND is relatively rare. Population-level data from the Netherlands, one of the most thoroughly studied countries, found an incidence of about 2.6 new cases per 100,000 people per year and a prevalence of roughly 9.5 per 100,000 at any given time. These figures are broadly consistent with rates reported across Europe, North America, and other high-income regions. MND is more common in men than women and typically appears between the ages of 50 and 70, though it can occur earlier. Geographic clustering has been observed in some areas, with both urban and rural pockets of higher risk identified, though the reasons remain unclear.
Ongoing Clinical Trials
Multiple therapies are currently in clinical trials. Several target specific genetic pathways, building on the approach used for tofersen. Ulefnersen, for example, is being studied for a different genetic subtype. Other trials are exploring stem cell therapies, including treatments derived from fat tissue and a product called lenzumestrocel, as well as immune-modifying approaches. These trials are actively collecting data across the UK and internationally, and their results over the coming years will determine whether the treatment landscape for MND broadens beyond the limited options available today.